A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

BACKGROUND: The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor prognosis. Trastuzumab improves overall survival but is associated with cardiotoxicity, especially a decline in left ventricular ejection fraction (LVEF). In addition, chemotherapy and radiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacquinot, Quentin, Meneveau, Nathalie, Chatot, Marion, Bonnetain, Franck, Degano, Bruno, Bouhaddi, Malika, Dumoulin, Gilles, Vernerey, Dewi, Pivot, Xavier, Mougin, Fabienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480259/
https://www.ncbi.nlm.nih.gov/pubmed/28629338
http://dx.doi.org/10.1186/s12885-017-3420-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480259/
https://www.ncbi.nlm.nih.gov/pubmed/28629338
http://dx.doi.org/10.1186/s12885-017-3420-4

Ejemplares similares